Joe Lennerz, MD, PhD, Chief Scientific Officer to Speak on Digital Pathology and AI in Diagnostics
BostonGene to Participate in Friends of Cancer Research Meeting
Media:
BostonGene
Erin Keleher
+1-617-283-2285
Erin.Keleher@BostonGene.com
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced its participation in the Friends of Cancer Research (Friends) meeting, Advancing the Future of Diagnostics and Regulatory Innovations. The event, which aims to drive innovation in diagnostics and regulatory policy, will be held on February 4 at the Ritz Carlton in Washington, DC.
The meeting will focus on advancing diagnostics and regulatory policy, with sessions addressing evidence generation for cutting-edge technologies like digital pathology and AI, strategies for developing tests for rare biomarkers and future regulatory considerations. New findings from the Digital PATH Project will be presented, which assessed variability in digital pathology platforms using a shared dataset. Key thought leaders will discuss how these innovations can drive precision medicine and improve patient outcomes.
BostonGene’s Chief Scientific Officer, Joe Lennerz, MD, PhD, will participate in the panel session, "Evaluating Digital Pathology and AI in Diagnostics," where he will share insights on the importance of high-quality data, the importance of ground truth and integrating new diagnostics entities and technologies into patient care.
- Date: Tuesday, February 4
- Time: 10:30 AM – 11:30 AM ET
To schedule a meeting during the event, contact Allie Lewan at allie.lewan@bostongene.com. For more event details, visit the Friends of Cancer Research website.
About BostonGene Corporation
BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit www.BostonGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250128475750/en/
